Page 3 - Daptorum Group News Today

Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | May 5, 2023

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology

Aptorum Group saw its market capitalization double following a busy week where the biopharmaceutical firm released its latest results and announced a merger...

Regulatory News: Aptorum Group Limited , today announced that its wholly owned subsidiary Aptorum Therapeutics Limited has entered into a non-binding Letter of Intent and Term Sheet to merge ... | May 1, 2023

Aptorum Group Limited (NASDAQ:APM – Get Rating) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 13,100 shares, a drop of 12.1% from the March 31st total of 14,900 shares. Approximately 1.4% of the shares of the company are short […]

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update New York & London & Paris, April 28, 2023 - Aptorum Group Limited , a... | April 28, 2023

Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | April 28, 2023

Aptorum Group Limited (NASDAQ:APM – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 14,900 shares, a growth of 11.2% from the March 15th total of 13,400 shares. Currently, 1.6% of the company’s shares are short sold. Based […]

A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,

URF Holding Group Limited URF Center 566 Middle Huaihai Road, Huangpu District Shanghai China Attn: Chief... | March 27, 2023